Shelter Pharma reported a strong FY2026 with revenue up 44% to ₹73.13 crore. The company plans a new manufacturing facility and raised ₹42.44 crore via preference shares for working capital.
Shelter Pharma Ltd. Reports Robust FY2026 Performance
Shelter Pharma's revenue from operations reached ₹73.13 crore in FY2026, marking a significant 44% year-on-year growth.
Reader Takeaway: Strong revenue growth and export traction, but high working capital and margin pressure persist.
What Just Happened
Shelter Pharma Ltd. announced its financial results for Fiscal Year 2026. The company posted revenue from operations of ₹73.13 crore, an increase of 44% compared to the previous year. EBITDA stood at ₹12.72 crore with a margin of 17.39%, and Profit After Tax (PAT) was ₹9.03 crore, achieving a margin of 12.3%. The company also raised ₹42.44 crore through preference share issuance.
Why This Matters
This performance indicates strong top-line growth for Shelter Pharma. The capital raised will support its expanding operations and sales force. However, investors need to watch the working capital cycle and margin recovery.
The Backstory
The company is operating in both the veterinary (55% of revenue) and human healthcare (45%) segments. Export revenue saw a substantial 164% year-on-year increase, reaching ₹6.00 crore in FY26. Shelter Pharma aims for ₹200 crore in revenue by FY2030.
What Changes Now
Shelter Pharma is planning a new manufacturing facility near Ahmedabad with an estimated capital expenditure of ₹12 crore to ₹15 crore, expected to start installation in 2027. This expansion will be funded by internal accruals.
Risks to Watch
The company is managing a high working capital cycle of 234 days, which management aims to reduce to 60-30 days. EBITDA margins have compressed due to investments in sales expansion, with expectations of recovery to 22-25% in 2-3 years.
Peer Comparison
Shelter Pharma's revenue from operations in FY26 was ₹73.13 crore. (Note: Specific peer comparisons require external data not provided in the filing.)
Context Metrics (Time-Bound)
- FY2026 Revenue: ₹73.13 crore (44% YoY growth)
- FY2026 EBITDA: ₹12.72 crore (17.39% margin)
- FY2026 PAT: ₹9.03 crore (12.3% margin)
- Export Revenue FY2026: ₹6.00 crore (164% YoY growth)
- Preference Share Issuance: ₹42.44 crore
- Planned Capex: ₹12-15 crore (for FY2027)
- Working Capital Cycle: 234 days (target 60-30 days)
What to Track Next
Investors should monitor the progress of the new manufacturing facility, the reduction in the working capital cycle, and the recovery of EBITDA margins in the coming quarters.